NASDAQ · INZY
Healthcare · Biotechnology
$4.00
Up+$0.01 (+0.25%)
Updated Aug 22, 2026, 8:54 AM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
INZY does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning INZY.
INZY research
Company profile and research snapshot.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 16, 2025 | Needham | Hold | — |
| May 16, 2025 | Wells Fargo | Equal-Weight | — |
| May 16, 2025 | Jefferies | Hold | — |
| May 14, 2025 | Needham | Buy | — |
| Apr 10, 2025 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Jun 20, 2025
Inozyme Pharma announced the postponement of its 2025 Annual Meeting of Stockholders due to the previously announced acquisition by BioMarin Pharmaceutical Inc. The company is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics targeting the PPi-Adenosine Pathway.
GlobeNewswire Inc. · May 18, 2025
Halper Sadeh LLC is investigating several companies, including SpringWorks Therapeutics, NV5 Global, Charter Communications, and Inozyme Pharma, for potential violations of securities laws and breaches of fiduciary duties to shareholders related to proposed mergers and acquisitions.
GlobeNewswire Inc. · Jul 2, 2024
Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency Agency program will support and expedite clinical studies addressing severe unmet need in children with ABCC6 Deficiency
GlobeNewswire Inc. · Jun 21, 2024
Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented Results from a radiographic study describing skeletal features of pediatric patients with ENPP1 Deficiency will be presented
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning INZY.
No results
No recent SID articles mention INZY.
